Breaking News
Get 40% Off 0
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March. Read full update
Close

Vaxxinity Inc (VAXX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Vaxxinity's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.1111 -0.0200    -15.26%
08/05 - Closed. Currency in USD ( Disclaimer )
After Hours
0.1129
+0.0018
+1.6202%
19:10:41 - Real-time Data
  • Volume: 2,928,938
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.1093 - 0.1243
Type:  Equity
Market:  United States
Vaxxinity 0.1111 -0.0200 -15.26%

Vaxxinity Inc Company Profile

 
Get an in-depth profile of Vaxxinity Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

61

Equity Type

ORD

Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer’s disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson’s disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer’s disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.

Contact Information

Address 505 Odyssey Way
Merritt Island, 32953
United States
Phone (254)244-5739
Fax -

Top Executives

Name Age Since Title
Thomas P. Monath 83 2022 Member of Science Advisory Board
Louis Garfield Reese 42 2014 Co-Founder & Executive Chairman of the Board
Peter H. Diamandis 63 2021 Non-Employee Independent Director
Stephen Nicholls - 2023 Member of Scientific Advisory Board
George Ronald Hornig 70 2022 Independent Director
Richard Mohs - - Member of Scientific Advisory Board
Jeffrey L. Cummings 74 - Member of Scientific Advisory Board
Landon Ogilvie 46 2023 Lead Independent Director
Frederick Raal - 2023 Member of Scientific Advisory Board
Kausik K. Ray - 2023 Member of Scientific Advisory Board
Stanley A. Plotkin 91 - Member of Scientific Advisory Board
Dirk Von Lewinski - 2023 Member of Scientific Advisory Board
Eric M. Reiman - - Member of Scientific Advisory Board
Nick Fox - - Member of Scientific Advisory Board
Wayne C. Koff - - Member of Scientific Advisory Board
James Alan Smith 43 2023 Independent Director
Gabrielle B. Toledano 57 2023 Independent Director
Parviz Ghahramani - 2023 Member of Scientific Advisory Board
Stephen D. Silberstein - 2023 Member of Scientific Advisory Board
Brad Boeve - - Member of Scientific Advisory Board
Mei Mei Hu 41 2014 CEO & Director
Thomas Fleming - 2023 Member of Scientific Advisory Board
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

VAXX Comments

Write your thoughts about Vaxxinity Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email